Ovid Therapeutics (NASDAQ:OVID) Issues Earnings Results

Posted by Geri Gentry on May 12th, 2026

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12), FiscalAI reports. Ovid Therapeutics had a negative return on equity of 23.98% and a negative net margin of 240.11%.

Ovid Therapeutics Stock Up 2.3%

Shares of NASDAQ:OVID traded up $0.06 during trading on Tuesday, hitting $2.85. 2,366,274 shares of the company were exchanged, compared to its average volume of 2,628,195. The firm’s 50 day moving average price is $2.41 and its 200-day moving average price is $1.86. Ovid Therapeutics has a 12-month low of $0.27 and a 12-month high of $3.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 8.97 and a quick ratio of 8.97. The stock has a market capitalization of $376.39 million, a P/E ratio of -9.11 and a beta of 0.18.

Hedge Funds Weigh In On Ovid Therapeutics

Several hedge funds have recently made changes to their positions in OVID. LPL Financial LLC boosted its position in shares of Ovid Therapeutics by 150.0% in the 4th quarter. LPL Financial LLC now owns 30,000 shares of the company’s stock valued at $49,000 after purchasing an additional 18,000 shares during the period. Bank of America Corp DE boosted its stake in shares of Ovid Therapeutics by 49.7% during the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock worth $53,000 after acquiring an additional 18,841 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Ovid Therapeutics by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 672,004 shares of the company’s stock worth $1,096,000 after acquiring an additional 23,984 shares during the period. Private Advisor Group LLC acquired a new position in shares of Ovid Therapeutics during the 3rd quarter valued at about $33,000. Finally, Invesco Ltd. bought a new position in Ovid Therapeutics in the fourth quarter valued at about $54,000. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Wall Street Analyst Weigh In

OVID has been the subject of a number of research analyst reports. Wall Street Zen upgraded Ovid Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ovid Therapeutics in a report on Tuesday, April 21st. HC Wainwright lifted their price target on shares of Ovid Therapeutics from $2.00 to $4.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price objective on shares of Ovid Therapeutics in a research note on Wednesday, April 15th. Finally, BTIG Research reissued a “buy” rating and issued a $4.00 price target on shares of Ovid Therapeutics in a report on Thursday, March 26th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ovid Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $4.63.

Check Out Our Latest Report on Ovid Therapeutics

Ovid Therapeutics Company Profile

(Get Free Report)

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.